Cell-Specific Neuropharmacology
Sarah Mondoloni, Romain Durand-de Cuttoli, Alexandre Mourot

To cite this version:

HAL Id: hal-02344518
https://hal.sorbonne-universite.fr/hal-02344518
Submitted on 4 Nov 2019

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L’archive ouverte pluridisciplinaire HAL, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d’enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.
Cell-specific neuropharmacology

Sarah Mondoloni1*, Romain Durand-de Cuttoli1,2* and Alexandre Mourot1*

1 Neuroscience Paris Seine - Institut de Biologie Paris Seine (NPS – IBPS), CNRS, INSERM, Sorbonne Université, Paris, France

2 Nash Family Department of Neuroscience, Center for Affective Neuroscience, and Friedman Brain Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA

* All the authors contributed equally to the work

Correspondence : alexandre.mourot@upmc.fr (A. Mourot)

Key words: optogenetics, chemogenetics, tethered ligand, bump-hole, receptor-ligand pair, photopharmacology
Abstract

Neuronal communication involves a multitude of neurotransmitters and an outstanding diversity of receptors and ion channels. Linking the activity of cell surface receptors and ion channels in defined neural circuits to brain states and behaviors has been a key challenge in neuroscience, since cell-targeting is not possible with traditional neuropharmacology. We review here recent technologies that enable the effect of drugs to be restricted to specific cell types, thereby allowing acute manipulation of the brain’s own proteins with circuit specificity. We highlight the importance of developing cell-specific neuropharmacology strategies for decoding the nervous system with molecular- and circuit-precision, and for developing future therapeutics with reduced side effects.
Probing the nervous system with cell-targeted drugs

Investigating the function of neurotransmitter receptors and ion channels has greatly benefited from both pharmacological and genetic techniques. Conditional mutagenesis and virally-delivered shRNAs enable the manipulation of proteins with molecular specificity and in targeted brain circuits, notably through the use of cre/lox recombination. Yet, these techniques do not have sufficient temporal resolution to establish a direct link between the activation of receptors and the modulation of circuits and behavior. In addition, they can lead to developmental alterations that compensate for those induced by the deletion/mutation of the receptor. In contrast, conventional pharmacology offers acute and often reversible control of endogenous proteins, enables graded alterations by varying drug concentration, and can be applied at any time in development. Nevertheless, pharmacology suffers from lack of functional selectivity, since small chemicals affect all types of neurons cannot be cell-targeted. This is especially an issue considering the wide distribution of ion channels and receptors in the brain, and the various functions they have in different cells or networks. Local distribution of drugs to precise brain regions may afford anatomical specificity, but has major drawbacks, such as the difficulty to control dosage and diffusion, and the inability to target specific neuronal types. Making small chemicals photocontrollable using caged compounds or photoswitches permits cellular or even subcellular optical targeting at the single cell level, and improves spatio-temporal control in vivo [1,2]. Yet, even with the most sophisticated light source, controlling receptors located on different cell types within the same circuit in an intact brain is elusive with optical techniques alone. The ability to acutely control signaling proteins in a complex environment such as the nervous system in a cellular- and circuit-specific manner and in the behaving animal should accelerate progress in our molecular understanding of brain function (Figure 1A).

The idea behind cell-specific pharmacology is to combine the acute onset of pharmacology with the cellular and molecular precision of genetics, to achieve acute control of signaling proteins in a cell-specific fashion. To this aim, several chemogenetic strategies have recently been developed, which we classify here in three categories (Figure 1, key figure, Table 1). The receptor-ligand pair approach (Figure 1B) consists in re-engineering proteins to make them sensitive to synthetic ligands. The key outcome is an increase in potency of the synthetic ligand
compared to the natural one (Figure 1C). The *tethered*-ligand approach (Figure 1D) relies on the anchoring of a ligand to the cell surface and results in an increased local concentration of the ligand. Anchoring can be performed either to a membrane-embedded element (membrane-tethered) or to a genetically-modified receptor (receptor-tethered). Finally, the last approach is to selectively deliver drugs to the cytoplasm of targeted cells, either using enzyme-prodrug pairs or facilitated diffusion through large ion channels (Figure 1E). Cell-specific neuropharmacology approaches provide the ability to test the function of receptors on specific types of neurons with unprecedented cellular precision (e.g. pre- vs. post-synaptic cells, or two different cell types within the same circuit) [3,4]. They also offer a unique opportunity to test the benefits of cell-targeted drugs for neurological and neuropsychiatric disorders. We review here these techniques, with a special focus on surface receptors and ion channels, highlighting their potentials and pitfalls, and the challenges they meet for *in vivo* use in rodents and for clinical applications.

**The receptor-ligand pair approach**

One central problem of traditional pharmacology is to identify small molecules that interact with a desired protein target with high specificity. This is especially challenging for proteins that belong to large protein families and therefore share a high degree of homology with other proteins in the cell. To address this shortcoming, a chemo-genetic strategy named **bump-hole** was developed, allowing inhibition of specific alleles of protein kinases [5]. The idea is to genetically create a hole on the catalytic active site of the protein, and to chemically modify the inhibitor, with a corresponding bump (Figure 1B). The synthetic ligand is **orthogonal**: it confers high specificity to the engineered enzyme, without affecting wild-type (WT) kinases. Importantly, the engineered kinase is a non-orthogonal mutant protein, i.e. it can still phosphorylate endogenous substrates. A wide range of kinase-inhibitor pairs were generated, displaying incomparable potency and specificity compared to known inhibitors [5].

Inspired by this approach, neuroscientists developed orthogonal receptor-ligand pairs, the most widely used being the Designer Receptors Exclusively Activated by Designer Drugs (DREADDs) [6,7]. DREADDs are modified G-protein coupled receptors (GPCRs) engineered through directed molecular evolution, that are insensitive to their natural ligands but sensitive
to synthetic agonists (Figure 2A). The original DREADDs (hM3Dq and hM4Di) are based on human M3 and M4 muscarinic receptors, which couple to Gq and Gi, respectively [6]. hM3Dq and hM4Di are made insensitive to acetylcholine (ACh), sensitive to the synthetic ligand clozapine-N-oxide (CNO), and importantly show minimal basal activity in the absence of chemical activation (but see [8]). hM3Dq is classically used for enhancing neuronal activity, while hM4Di is used for neuronal inhibition. Newer DREADDs include GsD that couples to Gs, hM4Dnrxn that is axonally targeted and affords pre-synaptic inhibition, and a κ-opioid-derived DREADD (KORD) that operates with salvinorin B [9], a compound distinct from CNO, thus allowing multiplexed and bidirectional modulation of neuronal activity and behavior.

Receptor-ligand pairs have also been developed for ligand gated ion channels (LGICs, Figure 2B). The ligand binding domain (LBD) of the α7 nicotinic acetylcholine receptor (nAChR), referred to as pharmacologically selective actuator module (PSAM), was engineered to respond solely to synthetic molecules called pharmacological selective effector molecules (PSEM) [10,11]. Activation of PSAM by PSEMs induces either cation, calcium or chloride influx, depending on the ion pore domain (IPD) spliced onto the LBD (serotonin 5HT3, α7-nAChR or glycine receptor IPD, respectively). Hence PSAMs can be used to either drive or suppress neuronal activity, or to increase intracellular calcium, in genetically-targeted neurons. DREADDS, and to a lesser extent PSAMs, have proven extremely valuable tools for the manipulation of circuits with cellular specificity, providing crucial information as to how circuits shape behavior [7,12]. However, because they are no longer sensitive to their cognate ligands, DREADDs and PSAMs are constraint to decode the nervous system at the circuit level, and cannot be used for the molecular dissection of the role of endogenous GPCR or LGIC signaling in the modulation of circuits and behaviors.

With the advent of optogenetics [13], light-based strategies for controlling brain proteins have emerged, affording improved spatio-temporal resolution over chemical approaches [1]. Notably, light-controllable adrenergic, opioid, serotoninergic and glutamateergic GPCRs (Opto-XRs) have been engineered [14,15]. Opto-XRs are chimeric proteins, usually engineered with a mammalian opsin (e.g. rhodopsin or melanopsin) and the intracellular loops and C-terminal tail of endogenous GPCRs (Figure 2C). In addition to trafficking and signaling like their native counterparts, OptoXRs are photo-activatable, offering the possibility to mimic the spatio-
temporal dynamics of neuromodulator signaling in vivo. Nevertheless, Opto-XRs bind retinal and therefore lack responsiveness to endogenous ligands, restricting their use, as with DREADDS, to a circuit-level understanding of brain function.

Dissecting the role of endogenous receptors and channels in behaviors requires maintaining their natural pharmacology and signaling properties. To this aim, two receptor-ligand pair-like approaches have been developed for GABA$_{A}$ receptors (GABA$_{A}$Rs) and nAChRs. GABA$_{A}$R signaling is potentiated by the allosteric modulator zolpidem, yet only when the $\gamma 2$ subunit is present in the receptor. A single mutation (phenylalanine to isoleucine) at position 77 on the $\gamma 2$ subunit is sufficient to convert a zolpidem-sensitive into a zolpidem-insensitive receptor (Figure 2D) [16]. In transgenic mice expressing $\gamma 2$(Ile77), sensitivity to zolpidem can be restored in a tissue-specific fashion using Cre-recombinases that switch $\gamma 2$(Ile77) to $\gamma 2$(Phe77).

Zolpidem-sensitivity was notably restricted to cerebellar Purkinje neurons, to show that potentiation of GABAergic inhibition in these cells induces motor deficits [17]. Even though motor deficits had been observed after zolpidem administration in WT mice, interpretation was ambiguous considering the profound sedative effects of this compound. Furthermore, mice with a deletion of $\gamma 2$ in Purkinje cells show no motor deficit, emphasizing the importance of developing cell-specific pharmacology approaches for acute interventions. Nevertheless, it should be noted that this strategy requires triple crosses of mouse lines, making it technologically demanding.

In nAChRs, the strategy was referred to as gain-of-function mutations [18]. The idea is to increase agonist sensitivity in a subtype-specific fashion using site-directed mutagenesis, and to use sub-threshold doses of nicotine for isoform-selective activation (Figure 2E). The leucine residue in position 9’ on the transmembrane (TM) segment M2 is a conserved residue that, when mutated to alanine, serine or threonine in the $\alpha$ subunit, considerably reduces the energy required to open the channel, resulting in a “hypersensitive” mutant with increased agonist sensitivity [18]. Using the Cre-lox technology, expression of such hypersensitive mutants could be restricted to specific neurons such as GABAergic cells of the ventral tegmental area or cholinergic neurons of the medial habenula, unveiling new roles for $\alpha 4$ nAChRs in reward and anxiety, respectively [19,20]. However, it should be noted that these
mutant receptors are also more sensitive to endogenous acetylcholine (ACh), which may result in unintended neuronal adaptations.

The tethered-ligand approach

The overall strategy is to increase local concentration of the drug at the cell surface through covalent attachment [21]. One major advantage of this approach is that once bio-conjugation is achieved, there is no need for reapplication of the drug.

Membrane-tethered ligands

A first example is based on genetically-encoded ligands that are self-embedded in cell membranes. The fusion construct is composed of a peptide linked by a flexible linker to the extracellular side of the membrane, either through a TM segment or a glycosyl-phosphatidylinositol (GPI) anchor (Figure 3A) [22-27]. The peptide ligand can either be an agonist (t-peptide) or an antagonist (t-toxin). This versatile approach has been successfully applied to activate class B GPCRs [22] and to inhibit specific voltage-gated sodium (Na,v) and calcium (Ca,v) channels as well as nAChRs [24-27]. Toxins can be extremely specific for a particular type of ion channel, enabling blockade of Na,v1.7 without affecting Na,v1.8 for instance [28]. However, since the ligand is permanently expressed at the membrane, the action of t-peptides and t-toxins is irreversible. T-toxin expression can be placed under the control of a Tet-on/Tet-off system, allowing antagonism to be triggered on and off, yet still with very slow kinetics (days) [24]. Consequently, these tools have been used for chronic inhibition of neuronal activity and genetic dissection of neurophysiological circuits rather than for acute, cell-specific pharmacology. T-toxins were notably used in freely-moving mice, where chronic inhibition of Ca,v2.1 and Ca,v2.2 allowed probing the role of thalamo-striatal excitatory synaptic transmission in the susceptibility to social stress [27].

An extension of this approach is to include in the construct a photosensitive group to afford reversibility. Notably, the light-oxygen voltage (LOV) protein domain from plants was used to produce Lumitoxins, light-controllable membrane-tethered toxins (Figure 2B) [29]. LOV domains incorporate a flavin chromophore, ubiquitously present in mammalian cells, and
changes conformation upon illumination with blue light. In darkness, Lumitoxins produce sustained block of voltage-gated potassium (Kv) channels, while illumination results in rapid (seconds) channel unblock. The LOV domain returns to its resting state slowly in darkness, restoring blockade within minutes. Specific Kv homologues such as Kv1.1, Kv1.2 or Shaker can be photosensitized using appropriate membrane-tethered toxins. However, this technique has not yet been extended to other protein families and has not been deployed in vivo.

Another strategy, called Drug Acutely Restricted by Tethering (DART), relies on a bacterial enzyme called HaloTag for capturing drugs at the cell surface [3]. HaloTag is a self-labeling enzyme that catalyzes the covalent attachment of synthetic molecules containing a HaloTag Ligand (HTL) with very high efficiency and specificity (Box 1). In DART, the HaloTag is expressed at the cell surface through a TM domain. The synthetic ligand is composed of an active drug linked to the HTL through a Poly-Ethylene Glycol (PEG) flexible linker. Once infused, it attaches to the HaloTag, resulting in a hundred-fold elevation of drug concentration at the cell surface.

This strategy is unique in that it offers acute pharmacological manipulation (seconds to minutes) of native receptors with cellular specificity. However, the effect is only very slowly reversible (days). DART has been applied to AMPA receptors (AMPARs) and metabotropic muscarinic receptors (mAChRs), showing that the method can be applied to different receptor types. Specific inhibition of AMPARs in distinct neuronal populations of the dorsal striatum (D1 versus D2 neurons) revealed that activity of these receptors is causally linked with the akinesia observed in a mouse model of Parkinson’s disease. Moreover, antagonism of AMPARs expressed on D2-, but not D1-, neurons had therapeutic effects on motor dysfunction, illustrating the power of targeting drugs to specific cell types.

**Receptor-tethered ligands**

Various strategies have been developed to tether ligands directly to their receptors. In the RECON (REductively Cleavable agONist) approach, a GPCR is N-terminally fused to a SNAP-tag [30], another type of self-labeling tag. The tethered ligand combines a peptide agonist for either class A or B GPCR, a central PEG linker bearing a disulfide bridge, and a SNAP-tag substrate. This synthetic ligand covalently and specifically attaches to the SNAP-tag, resulting in permanent receptor activation. The disulfide bridge can be cleaved with redox agents,
resulting in slow agonist dissociation. This method should be especially useful for studying GPCR activation and internalization in vitro; however, its use for neuropharmacology is elusive.

Increasing local agonist concentration at the receptor surface does not necessarily require covalent attachment. Another design is to install a His-tag on a GPCR, and to use a Metal-complex Agonist Conjugate (MAC) that binds with high affinity to the His-tag through coordination tethering (Figure 3D) [31]. Affinity of the synthetic ligand is 10-100 higher for the engineered than for the WT receptor. Interaction between MAC and the His-tag is not covalent, hence activation is reversible. The MAC strategy was used for cell-specific control of class A GPCRs (β2 adrenoreceptors and mACHRs), but its efficacy in vivo has not been reported yet.

One major drawback of tethered ligands is irreversibility of action. One solution to this issue is to incorporate a chemical photoswitch in the ligand, and use light to trigger binding/unbinding. This can be achieved by anchoring a photoswitchable tethered ligand (PTL) onto a cysteine-substituted receptor (Figure 3E). The cysteine mutation is incorporated in proximity to a ligand-binding site. The PTL is made of three elements: a maleimide moiety, which is a thiol-reactive group for attachment to cysteines; a central azobenzene photoswitch; and a bioactive ligand (agonist, antagonist or pore-blocker). Light is used to reversibly change the geometry of the photoswitch from elongated to twisted, which triggers binding/unbinding. This opto-chemogenetic strategy allows reversible control of receptors with very high spatial and temporal precision. The PTL approach has proven to be highly versatile. It has been applied to potassium channels [32-34], ionotropic [35-37] and metabotropic [38] glutamate receptors, nAChRs [4,39], GABA<sub>A</sub>Rs [40,41], dopamine receptors [42] as well as P2X receptors [43]. It was used to probe neurotransmission in various neuronal settings, both ex and in vivo in zebrafish and mice [1]. In zebrafish, the photoswitch can simply be added to the swimming water, but in mice it has to be locally delivered. Despite this drawback, the PTL approach has been applied in the living mouse, notably for restoring vision to blind mice [44], for manipulating action potential firing [45] and GABAergic inhibition [41] in the visual cortex, or for controlling nicotinic transmission in the ventral tegmental area and addiction-related behaviors [4]. One potential shortcoming of PTLs is their non-selective
attachment to endogenous cysteines, even though no adverse effect has been observed so far [4,41].

More specific bioconjugation (Box 1) can be achieved with the Photoswitchable Orthogonal Remotely Tethered Ligand (PORTL) approach, which uses self-labelling enzymes such as SNAP- or CLIP-tags (Figure 3F) [46-48]. These self-labeling tags can be fused directly to receptors [46,47] or alternatively to nanobodies [48], an interesting alternative for proteins for which incorporation of the tag is prohibited. Light is used to change the geometry of the ligand, and thereby its affinity for the protein. This technology has so far only been applied to metabotropic glutamate receptors, and was used to restore patterned vision in a blind mouse model [49].

Another alternative for site-specific bioconjugation is the Bio-Orthogonal Ligand Tethering (BOLT) technique, which is based on the incorporation of unnatural amino acids (UAA) in proteins [50]. The UAA is used as a biorthogonal handle for attachment of a synthetic ligand through click-chemistry. BOLT demonstrated selective inhibition of kinases in mammalian cells, and can be made photo-reversible by introducing a photoisomerizable group to the ligand (photoBOLT). Expansion of the genetic code in the mouse is technically challenging [51], but the recent generation of transgenic animals carrying a tRNA synthetase / tRNA pair into their genome should facilitate future use [52].

**Intracellular delivery approaches**

Intracellular, cell-specific delivery can also be achieved, allowing targeting not only cell-surface receptors but also enzymes and signaling pathways (Figure 1E). Two different approaches have been described.

**The enzyme-prodrug pair approach**

This approach relies on selective enzyme-substrate pairs to convert an inert prodrug into an active molecule (Figure 1E) [53]. The drug is masked by a disposable blocking group that is hydrolyzed specifically by an exogenous enzyme, but not by native ones. Expression of the
specific enzyme in genetically-targeted cells allows unmasking the drug in a cell-specific fashion. The challenges were to develop an ester masking group with high stability towards hydrolysis by endogenous esterases, and to find an esterase that would hydrolyze this ester bond with high efficiency. Screening resulted in the discovery of porcine liver esterase (PLE), an enzyme that efficiently hydrolyzes the cyclopropylmethyl carboxyl (CM) ester masking group [53]. More recently, another selective enzyme-substrate pair was developed, based on engineered variants of E. coli nitroreductase (NTR) and a nitroimidazol (NM) masking group [54]. This strategy has proven highly generalizable to various masked small molecules such as fluorophores, calcium indicators, enzyme inhibitors, cAMP analogs or ion channel blockers [53-55]. Notably, the masked compound CM-MK801 was used to confirm, in brain slices, the role of dopamine neuron-expressed NMDA receptors in cocaine-induced plasticity [55]. Both the CM and NM groups were shown to be highly stable in neurons, an important requirement for cell-specificity. That said, care must be taken because drugs that are too membrane permeable may diffuse out of the target neuron and affect nearby cells non-selectively. This limitation can be circumvented, for instance by increasing polarity of the compound [54]. The biggest challenge for future applications remains to use this technology in vivo. So far, the limited aqueous solubility of the masked compounds precludes direct brain delivery. In addition, systemic application of CM-masked drugs is prohibited as well because CM is not resistant to esterases expressed in the periphery.

**Facilitated diffusion through large ion-channel pores**

Another approach is based on the selective intracellular diffusion of membrane-impermeant drugs through large ion channels (Figure 1E). The capsaicin TRPV1 and some P2X receptors open a very large pore when activated, allowing permeation of large organic cations [56,57]. This biophysical property was ingeniously exploited to facilitate the entry of QX-314, a membrane-impermeant lidocaine derivative, into pain-sensing neurons [58]. QX-314 is normally inert on neurons because it has an intracellular site of action in Na₅s. However, it can selectively enter nociceptors by diffusing through open TRPV1 channels, which are abundant in these cells but virtually absent in other neurons. QX-314 remains trapped inside pain neurons for hours, resulting in long-lasting local analgesia [58-60]. To gain rapidly reversible control over nociception, we designed a photoswitchable version of QX-314, named QAQ [61-
63]. QAQ can rapidly and reversibly block Na$_v$s in nociceptors, switching pain signaling on and off upon illumination with the appropriate wavelength of light.

Unlike all the methods presented in this review, this strategy does not necessarily require genetic manipulation. Rather, it exploits the sparse distribution of TRPV1 channels or P2X receptors to achieve targeted cell loading, and thus bears potential therapeutic interest. So far, QX-314 and QAQ were co-administered with capsaicin to enable selective cell entry. Yet, recent studies suggest that capsaicin may not always be needed, since TRPV1 channels in central terminals are extensively hyperactive in neuropathic pain models [64]. Similarly, the retina was shown to be highly remodeled in animal models of retinal degeneration [65], with P2X receptors functionally upregulated in retinal ganglion cells [66]. This feature was exploited to deliver photoswitchable blockers of potassium channels [61,67] specifically to OFF-ganglion cells, thereby restoring visual responses to blind retinas [65,66].

**Concluding remarks**

Investigating the role of individual receptors and ion channels in particular brain regions requires methods for perturbing protein activity selectively, acutely, reversibly and in a cell-specific fashion, ideally in the behaving animal. Diverse methods are being developed toward this goal. Yet no method is universal, and virtually all have shortcomings, especially when considering their use *in vivo*. One important limitation lies in the limited therapeutic window for selective agonism / antagonism, which is classically in the range 10-100 fold (Table 1). Recent studies demonstrate that with some optimization, very potent agonists with exceptional selectivity (>10 000 fold) can be generated for PSAMs [11] and DREADDs [68], suggesting that such selectivity should be in principle attainable for other designer receptors. Full orthogonality can even be achieved, for instance using light-based methods (after ligand bioconjugation for PTLs and PORTLs). Yet, there is still a need for orthogonal labeling motifs that are efficient at lower doses (Box 1).

There is also a need for caution and appropriate controls when using chemogenetic approaches, even when reported to be fairly orthogonal. For instance, CNO was originally selected because of its excellent drug-like properties, but recent reports show that *in vivo* it is
metabolically back-converted to clozapine, a molecule that not only activates DREADDs but also many other endogenous GPCRs [69]. Importantly, non-CNO analogues with improved selectivity have been developed, notably compound 21 [70] and perlapine [68], circumventing this potential issue.

Another important limitation to consider is invasiveness. DREADD activators, PSEMs, nicotine and zolpidem have rapid central nervous system (CNS) penetration and distribution in mice and can therefore be applied systemically [7,17,18,71]. But other approaches require local drug delivery in brain tissue through a cannula guide, either because of the instability of the compound in aqueous medium (e.g. maleimide-based PTLs) or because of poor blood brain penetration (e.g. DART), or both. Methods for improved systemic delivery are awaited. Similarly, the optical tools described in this review classically work with visible light (Table 1) and therefore require local light delivery with a chronically implanted optic fiber. Red-shifted chromophores that operate at more deeply-penetrating wavelengths such as near-infra-red light are currently under development [72] and should facilitate remote, transcranial control in the future.

Another important aspect to consider is receptor-type specificity. Techniques like DART or intracellular delivery methods target native receptors and therefore cannot differentiate between different receptor isoforms expressed on the same cell. Toxin-based methods provide increased selectivity but whether they can be used for acute and reversible control of receptors and ion channels in vivo is unclear. On the other hand, methods that require genetic engineering of receptors, like PTL or PORTL, provide absolute receptor-type specificity and can help dissect the role of individual receptor subtypes in a circuit. However, molecular specificity comes at a cost: the requirement for ectopic expression of the target protein, which may affect expression level and/or patterns. Methods for overcoming this issue include the generation of transgenic knock-in animals [41] - ideally in a tissue-specific fashion - or the use of a subunit replacement strategy [34].

Finally, these tools bear strong potential not only for research purposes in animal models, but also for therapeutic applications in humans. Indeed, targeting drugs to particular neuronal populations may improve therapeutic efficacy, while decreasing the side effects associated
with insufficient selectivity of conventional approaches. For instance, QX-314 or QAQ can selectively block the function of pain-sensing neurons in rodents, while leaving other sensory modalities unaffected [58,59,62], and do not require genetic modification, making them potential drug-like candidates for pain-selective local anesthesia in humans. Approaches requiring genetic manipulation are also being explored to treat CNS diseases in a titrated and cell-specific manner. This includes strategies for restoring the balance of excitation/inhibition selectively in epileptogenic zones, or for treating movement disorder in Parkinson’s disease. The DART technology for instance revealed that antagonizing AMPARs expressed on D2 neurons of the basal ganglia was much more efficient at improving motor dysfunction than global antagonism through D1 and D2 neurons. Yet it is not clear how this finding can be translated into human therapy. DREADDs and PSAMs are currently progressing into non-human primates [73,74], an important step towards being used as treatment to people. In addition, hM4Di, KORD and new-generation PSAMs can be potently activated by low doses of olanzapine [75], salvinorin B [9] and varencline [71], respectively, three drugs that are already clinically approved, thus facilitating translation to humans. Despite these important advances, considerable obstacles for implementing such approaches to the clinic remain, notably those associated with gene therapy and, to a lesser extent, drug delivery and selectivity.
### Table 1: Cell-specific neuropharmacology approaches.

<table>
<thead>
<tr>
<th>Receptor-ligand pairs</th>
<th>Tool Name</th>
<th>Receptor</th>
<th>Ligand</th>
<th>On timescale</th>
<th>Off timescale</th>
<th>Therapeutic window (fold)</th>
<th>Application</th>
<th>In vivo application</th>
<th>Refs</th>
</tr>
</thead>
<tbody>
<tr>
<td>DREADDS</td>
<td>Synthetic GPCR</td>
<td>Synthetic (CNO, perlapine...)</td>
<td>s-min</td>
<td>min-hour</td>
<td>100-10000</td>
<td>On/off control of neuronal activity</td>
<td>Drosophila, mice, rats, monkeys</td>
<td>[6,7]</td>
<td></td>
</tr>
<tr>
<td>PSAM/PSEM</td>
<td>Synthetic LGIC</td>
<td>Synthetic (225, 895...)</td>
<td>s-min</td>
<td>min-hour</td>
<td>30-&gt;10000</td>
<td>On/off control of neuronal activity</td>
<td>Mice</td>
<td>[10,11]</td>
<td></td>
</tr>
<tr>
<td>Opto-XR</td>
<td>Opsin-GPCR chimera</td>
<td>Retinal + Blue light</td>
<td>ms-s</td>
<td>ms-s</td>
<td>Fully orthogonal (light)</td>
<td>Activation of G protein signaling</td>
<td>Mice</td>
<td>[14,15]</td>
<td></td>
</tr>
<tr>
<td>Zolpidem-insensitive GABA&lt;sub&gt;R&lt;/sub&gt;</td>
<td>Mutant GABA&lt;sub&gt;R&lt;/sub&gt;</td>
<td>Synthetic (Zolpidem)</td>
<td>s-min</td>
<td>min-hour</td>
<td>&gt;600</td>
<td>Modulation of GABA&lt;sub&gt;R&lt;/sub&gt;s</td>
<td>Mice</td>
<td>[17]</td>
<td></td>
</tr>
<tr>
<td>Gain of function nAChRs</td>
<td>Mutant nAChR</td>
<td>Exogenous (Nicotine) and endogenous (ACh)</td>
<td>s-min</td>
<td>min-hour</td>
<td>10-100</td>
<td>Activation of nAChR subtypes</td>
<td>Mice</td>
<td>[19,20]</td>
<td></td>
</tr>
<tr>
<td>Membrane-tethered ligands</td>
<td>t-toxins and t-peptides</td>
<td>Native receptors and ion channels</td>
<td>Genetically-encoded toxins or peptides</td>
<td>Always on (days with Tet-on system)</td>
<td>Irreversible (days with Tet-off system)</td>
<td>N.A. (constitutive)</td>
<td>Genetic dissection of circuits</td>
<td>Drosophila, zebrafish, mice</td>
<td>[22-27]</td>
</tr>
<tr>
<td>Lumitoxin</td>
<td>Native receptors and ion channels</td>
<td>Genetically-encoded toxins + blue light</td>
<td>min</td>
<td>s</td>
<td>Fully orthogonal (light)</td>
<td>Block of ion channel subtypes</td>
<td>N.R.</td>
<td>[29]</td>
<td></td>
</tr>
<tr>
<td>DART</td>
<td>Native AMPA receptors</td>
<td>HaloTag-reactive ligand</td>
<td>s-min</td>
<td>days</td>
<td>30-300</td>
<td>Antagonism of AMPARs and mACHRs</td>
<td>Mice</td>
<td>[3]</td>
<td></td>
</tr>
<tr>
<td>Receptor-tethered ligands</td>
<td>RECON</td>
<td>SNAP-tagged GPCR</td>
<td>SNAP-reactive ligand</td>
<td>s-min</td>
<td>Irreversible (min with redox agent)</td>
<td>N.A.</td>
<td>Activation and internalization of GPCRs</td>
<td>N.R.</td>
<td>[30]</td>
</tr>
<tr>
<td>MAC</td>
<td>His-tagged GPCR</td>
<td>Metal complex-agonist conjugate</td>
<td>s-min</td>
<td>min</td>
<td>10-100</td>
<td>Activation of GPCRs</td>
<td>N.R.</td>
<td>[31]</td>
<td></td>
</tr>
<tr>
<td>PTL</td>
<td>Cysteine-substituted receptor</td>
<td>Thiol-reactive ligand + UV-visible light</td>
<td>ms-s</td>
<td>ms-s</td>
<td>N.A. (orthogonal after attachment)</td>
<td>On/off control of receptors and ion channels</td>
<td>Zebrafish, mice</td>
<td>[4,32-43]</td>
<td></td>
</tr>
<tr>
<td>PORTL</td>
<td>SNAP- or CLIP-tagged GPCR or nanobody</td>
<td>SNAP- or CLIP-reactive ligand + UV-visible light</td>
<td>ms-s</td>
<td>ms-s</td>
<td>N.A. (orthogonal after attachment)</td>
<td>On/off control of receptors</td>
<td>Mice</td>
<td>[46-48]</td>
<td></td>
</tr>
<tr>
<td>iBOLT (and photoBOLT)</td>
<td>Receptor mutated with unnatural aminoacid</td>
<td>Click chemistry-reactive ligand (+ UV light)</td>
<td>min-h</td>
<td>Irreversible (min with light)</td>
<td>N.A.</td>
<td>Inhibition of protein activity (reversible with light)</td>
<td>N.R.</td>
<td>[50]</td>
<td></td>
</tr>
</tbody>
</table>

**Intracellular delivery**
<table>
<thead>
<tr>
<th>Enzyme-pro drug pair</th>
<th>Native proteins</th>
<th>Masked drug</th>
<th>min</th>
<th>Irreversible</th>
<th>N.A.</th>
<th>Control of protein activity</th>
<th>N.R.</th>
<th>[53-55]</th>
</tr>
</thead>
<tbody>
<tr>
<td>Facilitated diffusion through large ion channels</td>
<td>Native proteins</td>
<td>Membrane-impermeant and cationic (+UV-visible light)</td>
<td>Min (ms-s with light)</td>
<td>Days (ms-s with light)</td>
<td>N.A.</td>
<td>Block of ion channels (on/off with light)</td>
<td>Mice, rats</td>
<td>[58-60,62, 63,65, 66]</td>
</tr>
</tbody>
</table>

**Acknowledgement:** We wish to thank Fabio Marti and Philippe Faure (Sorbonne Université) for their comments on the manuscript. This work was supported by grants from the Fondation pour la Recherche Médicale FRM (Equipe FRM DEQ2013326488), the Brain and Behavior Research Foundation (NARSAD Young Investigator Grant), the Agence Nationale de la Recherche (ANR-JCJC), the Institut National Du Cancer (TABAC-16-022) and the Fondation de France (Fondation Médisite). SM and RDC were recipient of a 4th year PhD fellowship from FRM (FDT201904008060 and FDT20170437427, respectively).
References


Buhr, A. *et al.* (1997) Subtle changes in residue 77 of the gamma subunit of alpha1beta2gamma2 GABAA receptors drastically alter the affinity for ligands of the benzodiazepine binding site. *Journal of Biological Chemistry* 272, 11799–11804


Sandoz, G. et al. (2012) Optical Control of Endogenous Proteins with a Photoswitchable Conditional Subunit Reveals a Role for TREK1 in GABAB Signaling. *Neuron* 74, 1005–1014


Tochitsky, I. et al. (2012) Optochemical control of genetically engineered neuronal
nicotinic acetylcholine receptors. *Nature Chemistry* 4, 105–111


Han, S. *et al.* (2017) Expanding the genetic code of Mus musculus. *Nature Communications* 8, 1–7

Tian, L. *et al.* (2012) Selective esterase-ester pair for targeting small molecules
with cellular specificity. *Proceedings of the National Academy of Sciences* 109, 4756–4761


Tochitsky, I. *et al.* (2016) How Azobenzene Photoswitches Restore Visual Responses to the Blind Retina. *Neuron* 92, 100–113


Thompson, K.J. et al. (2018) DREADD Agonist 21 Is an Effective Agonist for Muscarinic-Based DREADDs in Vitro and in Vivo. ACS Pharmacology & Translational Science 1, 61–72

Magnus, C.J. et al. (2019) Ultrapotent chemogenetics for research and potential clinical applications. Science 364,


Glossary

Azobenzene, chemical photoswitch that can be reversibly isomerized between an elongated trans state and a twisted cis isomer with short (classically near-UV) and long (blue-green) wavelengths of light, respectively.

BOLT, bioorthogonal ligand tethering. Ligand is conjugated to an UAA through click-chemistry.

Bump-hole, strategy based on the enlargement of binding sites (holes) in proteins (initially enzymes) to make them selective to complementary “bumped” ligands.

Click chemistry, orthogonal bioconjugation reaction that is rapid, biocompatible and high yielding.

CM, cyclopropylmethyl carboxyl. Masking group cleaved selectively by PLE.

Cre/lox recombination, genetic manipulation based on an enzyme, Cre recombinase, and its recognition site, lox P, used for tissue-specific gene expression.

DART, drugs acutely restricted by tethering. Method for capturing drugs at the cell surface using a HaloTag.

DREADDs, Designer Receptors Exclusively Activated by Designer Drugs. Engineered GPCRs that exclusively respond to synthetic ligands.

GPI anchor, glycolipid (Glycosylphosphatidylinositol) that can be attached to the C-terminus of a protein.

His-tag, tag made of 4 to 9 histidine residues (4 in the MAC technology) classically used for purification of recombinant proteins.
**LOV domain**, light-oxygen voltage domain. Blue light sensor from algae, plants, bacteria and funghi, used to control cellular responses with light.

**MAC**, metal complex-agonist conjugates. Bifunctional ligand containing a Ni$^{2+}$-nitrilotriacetic acid (Ni-NTA) moiety for selective coordination tethering to his-tagged receptors.

**Maleimide**, 1H-pyrrole-2,5-dione. Cysteine-reactive chemical group.

**NM**, 2-nitro-N-methylimidazolyl. Masking group selectively unmasked with NTR.

**NTR**, Nitroreductase from *E. Coli* used for selective reduction of NM groups.

**Opto-XR**, chimeric photocontrollable receptor engineered using opsins and the intracellular loops or N-terminal tail of mammalian GPCRs.

**Orthogonal**, which does not interfere with native biological processes.

**PEG**, polyethylene glycol. Flexible polymer that is highly water soluble.

**PLE**, porcine liver esterase. Exogenous enzyme that efficiently and selectively hydrolyses CM ester substrates.

**PORTL**, photoswitchable orthogonal remotely tethered ligand. Photoswitchable ligand tethered to a protein or nanobody through SNAP- or CLIP-tag conjugation.

**PSAM/PSEM**, Synthetic protein (pharmacologically selective actuator module, PSAM) that is selectively activated by synthetic ligands (pharmacologically selective effector molecules, PSEMs).

**PTL**, photoswitchable tethered ligand. Thiol-reactive ligand incorporating a chemical photoswitch, that photosensitizes cysteine-substituted receptors and ion channels.
QAQ, Quaternary-ammonium azobenzene quaternary-ammonium. Light-sensitive blocker of voltage-gated potassium and sodium channels, used as a photoreversible local anesthetics.

shRNAs, short (or small) hairpin RNA used to silence gene expression.

SNAP-, CLIP- and Halo-tags, Protein-based self-labeling tags, catalyzing the formation of a specific, covalent bond between a labeling molecule and a tag-fused protein of interest.

Tethered, covalently (irreversibly) anchored.

Tet-on/off system, tetracycline (Tet) approach for precise and reversible spatiotemporal control of gene expression.

Thiol, side chain of the amino acid cysteine, which imparts reactivity to maleimides for ligand tethering.

UAA, unnatural amino acid. Synthetic amino acid which can be incorporated in proteins using the Amber stop codon technology.
Figure legends

Figure 1 – Cell-specific neuropharmacology strategies. A. Cell-specific pharmacology concept. A drug (green) is delivered to the whole organism but targets only specific types of neurons in the brain. The approach allows to evaluate the neurophysiological and behavioral consequences of the manipulation of receptors in discrete circuits of the brain. B. Bump-hole strategy. Top: the ligand (agonist or antagonist, green) acts on wild-type proteins. (Bottom left) The engineered protein contains a “hole” in the binding pocket, while the synthetic ligand (purple) contains a corresponding “bump”. The mutant protein is non-orthogonal because it remains sensitive to the endogenous ligand (green). The orthogonal ligand acts specifically and exclusively on the engineered protein. (Bottom right) Both the modified protein and the synthetic ligand are orthogonal. C. Leftward shift in the concentration-response curve for the synthetic ligand (purple) compared to the natural agonist or antagonist (green). D. Tethered-ligand approaches developed for G-protein coupled receptors (GPCRs), ligand-gated (LGICs) and voltage-gated ion channels (VGIC). (Left) The ligand is either embedded in the cell membrane (membrane-tethered) or tethered to the receptor itself (receptor-tethered). E. Intracellular delivery approaches. The drug is inactive in the extracellular space, and gets active only after it has entered targeted cells. Color coding throughout figures A-E: native proteins are shown in light grey and engineered ones in dark grey.

Figure 2 – The receptor-ligand pair approach. A. Designer Receptors Exclusively Activated by Designer Drugs (DREADDs). DREADDs are orthologous receptor-ligand pairs made of a modified human muscarinic receptor (hM), with mutations in transmembrane domains (orange), that is insensitive to its natural agonist acetylcholine (ACh), but is exclusively activated by a synthetic ligand (e.g. clozapine-N-oxide, CNO). B. The Pharmacologically Selective Actuator Module/Effecter Molecules (PSAM/PSEM) strategy: PSAM is an orthogonal, engineered ligand binding domain (LBD) of the homopentameric α7-nAChRs that is solely activated by PSEM (and not ACh). Different ion pore domains (IPDs) can be spliced on the PSAM allowing calcium, cation or chloride permeation. C. The Opto-XR approach: Opsin-GPCR chimeras are made of the intracellular domains of mammalian GPCRs (such as β2- and α1-adrenergic receptors, grey) swapped on the transmembrane (TM) domain of mammalian opsin (e.g. rhodopsin, blue). Opto-XRs are not sensitive to endogenous ligands (e.g.
norepinephrine, NE). They contain a retinal chromophore (blue) and enable the optical control of intracellular signaling transduction. D. Zolpidem (pink) potentiates GABA signaling by binding to GABA\(_A\)Rs that contain the \(\gamma2\) subunit. Substitution of phenylalanine (F) 77 by isoleucine (I) on \(\gamma2\) induces a loss of response to zolpidem. E. Mutation of the leucine residue in position 9' (L9'), for instance to Alanine (A), leads to a "hypersensitive" nAChR that is activated with subthreshold concentrations of the agonist nicotine.

**Figure 3 – The tethered ligand approach.** A. t-Toxins and t-Peptides are genetically-encoded ligands permanently tethered to the cell surface through either a glycosylphosphatidylinositol (GPI) anchor (depicted here) or a transmembrane domain (TM). B. Lumitoxin are chimeric proteins composed of a TM, a light-oxygen-voltage (LOV) domain, a linker and a toxin (green). In darkness, Lumitoxin blocks endogenous potassium channels at the cell surface, while illumination with blue light unfolds LOV and relieves blockade. C. The Drug Acutely Restricted by Tethering (DART) strategy is based on the expression of a TM anchor linked to a specific self-labeling protein tag (e.g. HaloTag), allowing the capture of a specific ligand to the cell surface. The ligand is composed of a HaloTag Ligand (HTL), a flexible linker (polyethylene glycol, PEG) and a ligand (green). Conjugation results in a 100-fold increased concentration of the ligand at the cell surface. D. Specific binding of a Metal complexe-Agonist Conjugate (MAC) to a His-Tagged GPCR, through coordination between the Ni\(^{2+}\)-nitrilotriacetic acid (Ni-NTA) group of the ligand and the His-Tag. E. Photoswitchable tethered ligands (PTLs) are composed of a cysteine reactive group (maleimide, grey), a photosensitive azobenzene core (orange), and a ligand (green). PTLs covalently attach to an engineered receptor that contains a single cysteine substitution, near the ligand binding site, thereby affording reversible photocontrol. F. Photoswitchable orthogonal remotely tethered ligands (PORTLs) are composed of a ligand, a photoswitchable azobenzene molecule, a flexible linker and a benzylguanine (BG) or benzylcytosine (BC) group for conjugation to SNAP- or CLIP-Tags, respectively.

**Figure 4: Intracellular delivery approaches.** A. The enzyme-prodrug pair approach relies on the use of a masked prodrug, and an exogenous enzyme that coverts the prodrug into an active drug. B. The facilitated diffusion approach uses large ion channels such as TRPV1 or P2X receptors for the selective entry of membrane-impermeant drugs. Here the drug is photocontrollable, enabling on and off action at the target protein with two distinct
wavelengths of light.

Box 1: Bioconjugation technologies.

Bioconjugation reagents are used to link together a small chemical molecule (e.g. a ligand) and a protein of interest (POI). Chemically tagging a protein with low toxicity and high specificity in a complex cellular environment is a challenge. It requires genetic modification of the POI, in order to incorporate a reactive group that will serve as a biorthogonal handle for conjugation. Multiple strategies exist [76]. The smallest and least disruptive genetic modification is the incorporation of a cysteine amino acid on the protein surface through site-directed mutagenesis. Cysteines contain a thiol group that reacts efficiently, rapidly (minutes) and with high selectivity with maleimide groups (Figure I) to form stable, covalent adducts [76]. Cysteine has become the primary choice for site-specific modification of membrane proteins because it is relatively low abundant, often engaged in disulfide bridges, and highly nucleophilic at neural pH [21]. Importantly, due the strong reductive environment of the cytoplasm, cysteine-maleimide conjugation chemistry is restricted to extracellularly-accessible sites on membrane proteins [21]. In addition, because cysteines are naturally present on many endogenous proteins, novel bioconjugation techniques that work inside cells and that are fully bio-orthogonal have been developed. This includes the use of unnatural amino acids (UAA) that contain a double (alkene) or triple bond (alkyne) for bioconjugation with tetrazine-containing ligands through click chemistry [50] (Figure I). Click-chemistry is extremely popular for protein bioconjugation because it relies on chemical groups that are highly selective toward each other -yet remain inert otherwise-, exhibits fast reaction kinetics in aqueous media (minutes) and produces adducts that are very stable [76]. However, UAAs must be incorporated into proteins through Amber codon suppression technology, which remains challenging in vivo [52]. The other approaches for orthogonal labeling rely on larger modifications of the POI, such as the incorporation of polypeptide tags. For instance, metal chelation methods using poly-histidine tags (His-tag), which are classically used for protein purification, have been used for non-covalent labeling with Ni-NTA ligands [31]. His-tags are small (4-9 residues), conferring minimal disturbance to the protein, and label probes with high efficiency and selectivity. Nevertheless, labeling is reversible and Ni is toxic to cells, hampering in vivo use [76]. Finally, self-labeling domains such as SNAP-, CLIP- or HALO-tags use enzyme-
catalyzed reactions for irreversible conjugation of ligands to POI in live cells. The reaction is highly biorthogonal, rapid, irreversible and works intracellularly with low concentration of substrate (nanomolar range) [76], but requires fusion of the POI with a large protein domain (>20 kDa) at the N- or C-terminus, which either is prohibited (as with nAChRs or GABAαRs for instance) or may affect POI function.

Box1 Figure I. Representative reactive groups for protein-ligand bioconjugation.
**Highlights**

Chemogenetic technologies that combine the speed of pharmacology with the cellular precision of genetics are emerging, enabling acute control of neuronal receptors with circuit specificity.

Targeting drugs to specific neuronal types usually requires genetic manipulation of either the target protein or the target cell.

*In vivo* implementation of these technologies allows unprecedented control of circuits at the molecular level, and help unambiguously link the activity of specific receptors to behavioral functions.
Is multiplexing possible? Only some of the methods described here allow for multiplexed interrogation across cell- (DREADDs, PSAM, DART) and receptor-types (PORTL). Notably, CLIP-mGluR2 and SNAP-mGluR7 expressed in the same cell could be labeled and manipulated with orthogonal reactivity and wavelengths, respectively [41]. Nevertheless, novel approaches for concurrent delivery of two or more drugs to distinct cellular populations are needed.

Can DART be made photo-reversible? One current limitation of the DART technology is its slow reversal. In principle, adding a photo-isomerizable linker could help accelerate the off rate, as in the PORTL approach. However, DART and PORTL have two major differences: ligand/receptor stoichiometry and fixed vs. variable distance between the receptor and the anchor. It will be interesting to determine whether DART can be made photo-controllable.

Can fully bio-orthogonal groups be developed for tethered ligands? Most of the functional groups described in this review are not fully orthogonal, causing non-specific labeling in live cells. Others are too large (SNAP, CLIP…) and may affect protein function. Some groups are too lipophilic and have limited bioavailability. And most of them cannot pass the blood brain barrier and therefore have to be delivered locally into the brain. Hence, numerous challenges remain in bio-orthogonal chemistry in live cells.
A.

Bump-Hole

B. Bump-Hole

Wild-type protein

Orthogonal ligand

Agonist or antagonist

Orthogonal mutant protein

Non-Orthogonal mutant protein

C.

Response (% of max)

Log [ligand]

D. Membrane-tethered ligand

Receptor-tethered ligand

E. Intracellular delivery approaches

FIGURE 1
**FIGURE 2**

A. **DREADDs**

- ACh
- CNO
- hM3Dq
- hM4Di
- Rhodopsin
- β2-AR
- Gq
- Gi
- α7nAChR
- PSAM
- PSEM
- IPD
- LBD
- Cations
- Cl-
- Ca2+
- α
- β
- γ2

B. **PSAM/PSEM**

- ACh
- NE
- α1-AR
- Gq
- Gaq
- α7nAChR
- PSAM
- PSEM
- IPD
- LBD
- Cations
- Cl-
- Ca2+

C. **Opto-XRs**

- β2-AR
- α1-AR
- Rhodopsin
- Gq
- Gaq

D. **Zolpidem-insensitive GABA_A receptors**

- Zolpidem sensitive
- Zolpidem insensitive
- γ2
- WT nAChR
- α L9'A nAChR
- Subthreshold Nicotine
- Na+, Ca2+

E. **Gain of function nAChRs**

- subthreshold nicotine
- WT nAChR
- α L9'A nAChR
- Na+, Ca2+
- Zolpidem-insensitive GABA_A receptors
- Gain of function nAChRs
FIGURE 4

A. Enzyme–prodrug pair

- Masked Enzyme
- Native receptors/channels
- Blocker

B. Facilitated diffusion

- P2X
- TRPV1
- hv₁
- hv₂

Figure 4